# OnCo record neoadjuvant-versus-upfront-surgery-pancreatic (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/neoadjuvant-versus-upfront-surgery-pancreatic/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "neoadjuvant-versus-upfront-surgery-pancreatic" ;
  schema:name "Neoadjuvant therapy versus surgery first for resectable and borderline resectable pancreatic cancer"@en ;
  schema:alternateName "Surgery-first versus chemotherapy-first in pancreatic cancer"@en, "Perioperative chemotherapy pancreatic cancer"@en, "Total neoadjuvant therapy for pancreatic cancer"@en, "Preoperative chemotherapy pancreatic cancer"@en, "PREOPANC question"@en, "NORPACT question"@en ;
  schema:description "For pancreatic cancers that look removable, doctors debate whether to operate at once and give chemotherapy afterwards, or to give chemotherapy first. Trials show chemotherapy first helps when the tumour is borderline, touching the big vessels, but it is not yet proven better for clearly removable tumours, where the largest trial found no gain and a US trial is still running."@en ;
  schema:url <https://onco.cc/terms/neoadjuvant-versus-upfront-surgery-pancreatic/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neoadjuvant_therapy> ;
  schema:citation <https://doi.org/10.1200/jco.21.02233>, <https://doi.org/10.1016/j.ejca.2021.10.023>, <https://doi.org/10.1245/s10434-024-15817-5>, <https://clinicaltrials.gov/study/NCT04340141>, <https://www.nice.org.uk/guidance/ng85/chapter/Recommendations>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455> ;
  onco:tag "gi", "pancreatic" ;
  onco:related <https://onco.cc/ideas/idea-ras-inhibitor-neoadjuvant-pdac/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/borderline-resectable-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/terms/chemoradiation/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/nccn-resectability-criteria-pancreatic/>, <https://onco.cc/terms/r0-r1-margin-pancreatic/>, <https://onco.cc/terms/resectability/>, <https://onco.cc/terms/downstaging/> ;
  onco:trials <https://onco.cc/trials/preopanc/>, <https://onco.cc/trials/norpact-1/>, <https://onco.cc/trials/prodige-24/> .